Sickle Cell Disease: Rapid, Low-Cost Diagnostic Platform GazelleTM Could Improve Care in Remote Regions

Sickle cell disease (SCD) is a major public health issue in India that warrants immediate diagnosis to avoid deaths in affected populations. Delays in diagnosing SCD could be detrimental to the person suffering from the disease.

Business Wire reported that researchers from the National Institute of Research in Tribal Health (NIRTH) in India reviewed a diagnostic platform that has been approved in other countries to look for a rapid, low-cost, point-of-care, diagnostic tool to diagnose sickle cell disease (SCD) in remote regions in India.

They found that it yielded a high accuracy of 99% compared to reference standard tests, like hemoglobin electrophoresis and HPLC.